Patents by Inventor Sachdev Sidhu

Sachdev Sidhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250043012
    Abstract: Described herein are antibodies that bind EGFR domain II and/or Domain III. Also described are bispecific antibodies that bind domain II and domain II of EGFR. Also described are methods and uses for treating cancer.
    Type: Application
    Filed: March 8, 2023
    Publication date: February 6, 2025
    Inventors: Sachdev SIDHU, Jarrett ADAMS, Max LONDON, Dewald van DYK
  • Publication number: 20240383988
    Abstract: Described herein are antibodies that bind EGFR domain II and/or Domain III. Also described are bispecific antibodies that bind domain II and domain II of EGFR. Also described are methods and uses for treating cancer.
    Type: Application
    Filed: June 24, 2022
    Publication date: November 21, 2024
    Inventors: Sachdev SIDHU, Jarrett ADAMS, Max LONDON, Dewald VAN DYK
  • Publication number: 20240228631
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: November 3, 2023
    Publication date: July 11, 2024
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Publication number: 20240182549
    Abstract: Described herein are peptides and peptide-antibody fusions that bind to the SARS-CoV-2 S protein and the receptor binding domain (RED), and methods for using the compositions containing these antibodies in the treatment of COVID-19, Specifically, we developed novel CoV-2 S protein binding peptides making use of a naïve phage-displayed 16mer peptide library—wherein the CoV-2 S protein binding peptides bind epitopes in both the RBD and S protein outside of the RBD. In addition, we show that fusion of these peptides to the N-terminus of nAbs improves their apparent affinity, potency and breadth of neutralization, without compromising their developability profile, Thus, these peptides represent a novel class of SARS-CoV-2 S protein binders, which can be formatted in various ways to improve functional properties of nAbs to be used in the treatment of many different diseases.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 6, 2024
    Inventors: Sachdev SIDHU, Shane MIERSCH, Gang CHEN, Jonathan LABRIOLA
  • Publication number: 20240132600
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: November 2, 2023
    Publication date: April 25, 2024
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Patent number: 11649561
    Abstract: There is provided herein a method for identifying and/or recovering at least one genetically encoded affinity reagent specific for a target molecule by screening using molecular display in conjunction with the sequencing of positive and negative selection pools from the screen.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: May 16, 2023
    Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Sachdev Sidhu, Jason Moffat, Helena Persson, Nish Patel, Saravanan Sundararajan, Amandeep Gakhal, Wei Ye, Jelena Tomic, Megan Mclaughlin
  • Publication number: 20230118983
    Abstract: Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.
    Type: Application
    Filed: June 22, 2022
    Publication date: April 20, 2023
    Inventors: Stephane ANGERS, Sachdev SIDHU, Levi BLAZER, Jarrett ADAMS, Somasekar SESHAGIRI
  • Publication number: 20220315659
    Abstract: Described herein are methods to affect binding by a multivalent binding molecule to a FZD receptor and a Wnt co-receptor on a cell wherein binding by the multivalent binding molecule to both FZD receptor and co-receptor on the cell activates a Wnt signaling pathway. Also described herein are multivalent binding molecules comprising a FZD receptor binding domain and a Wnt co-receptor biding domain on either end of an Fc domain that activate a Wnt signaling pathway and methods for their use.
    Type: Application
    Filed: June 10, 2020
    Publication date: October 6, 2022
    Inventors: Stephane ANGERS, Sachdev SIDHU, Yuyong TAO
  • Publication number: 20220235123
    Abstract: The invention provides novel synthetic antibodies directed against VEGF and uses thereof.
    Type: Application
    Filed: November 18, 2021
    Publication date: July 28, 2022
    Inventors: FREDERIC FELLOUSE, JASON MOFFAT, SACHDEV SIDHU, CHANIYILPARAMPI NANAPPAN RAMCHAND, RAVIKANT HARIT, REENA ARORA, AJU ANTONY, SANTHI VINODH
  • Publication number: 20220073640
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Application
    Filed: October 26, 2021
    Publication date: March 10, 2022
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal
  • Patent number: 11254738
    Abstract: The invention provides novel synthetic antibodies directed against VEGF and uses thereof.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: February 22, 2022
    Assignees: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO BANTING INSTITUTE, SAKSIN LIFESCIENCES PVT. LTD.
    Inventors: Frederic Fellouse, Jason Moffat, Sachdev Sidhu, Cn Ramchand, Ravikant Harit, Reena Arora, Aju Antony, Santhi Vinodh
  • Patent number: 11220551
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: January 11, 2022
    Assignees: The Governing Council of the University of Toronto, McMaster University
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal
  • Patent number: 11174308
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: November 16, 2021
    Assignees: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • Publication number: 20210292394
    Abstract: The present invention addresses a need for antibodies useful for filovirus infections.
    Type: Application
    Filed: December 28, 2020
    Publication date: September 23, 2021
    Inventors: Jonathan R. Lai, Jayne F.. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
  • Patent number: 11124575
    Abstract: An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: September 21, 2021
    Assignees: University of Saskatchewan, The Governing Council of the University of Toronto
    Inventors: Sachdev Sidhu, Shane Miersch, Clarence Ronald Geyer
  • Publication number: 20210253718
    Abstract: The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression of activity of Frizzled protein.
    Type: Application
    Filed: February 15, 2021
    Publication date: August 19, 2021
    Inventors: Guohua Pan, Jason Moffat, Sachdev Sidhu, Stephane Angers, Zachary Steinhart, Xiaowei Wang
  • Publication number: 20210148928
    Abstract: There is provided herein a method for identifying and/or recovering at least one genetically encoded affinity reagent specific for a target molecule by screening using molecular display in conjunction with the sequencing of positive and negative selection pools from the screen.
    Type: Application
    Filed: August 14, 2020
    Publication date: May 20, 2021
    Inventors: Sachdev Sidhu, Jason Moffat, Helena Persson, Nish Patel, Saravanan Sundararajan, Amandeep Gakhal, Wei Ye, Jelena Tomic, Megan Mclaughlin
  • Patent number: 10919968
    Abstract: The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression or activity of Frizzled protein.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 16, 2021
    Assignee: MODMAB THERAPEUTICS CORPORATION
    Inventors: Sachdev Sidhu, Jason Moffat, Stephane Angers, Zachary Steinhart
  • Publication number: 20210032352
    Abstract: Described herein are methods to affect binding by a multivalent binding molecule to a FZD receptor and a Wnt co-receptor on a cell wherein binding by the multivalent binding molecule to both FZD receptor and co-receptor on the cell activates a Wnt signaling pathway. Also described herein are multivalent binding molecules comprising a FZD receptor binding domain and a Wnt co-receptor biding domain on either end of an Fc domain that activate a Wnt signaling pathway and methods for their use.
    Type: Application
    Filed: February 14, 2019
    Publication date: February 4, 2021
    Applicant: AnterA Therapeutics Inc.
    Inventors: Stephane ANGERS, Sachdev SIDHU, Yuyong TAO
  • Patent number: 10875907
    Abstract: The present invention addresses a need for antibodies useful for filovirus infections.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 29, 2020
    Assignees: Albert Einstein College of Medicine, The Governing Council of the University of Toronto, The Government of the United States as Represented by the Secretary of the Army
    Inventors: Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak